Reverse transcription, also known as cDNA synthesis from an RNA template, is carried out by reverse transcriptases (RTs), an enzyme. To direct the synthesis of the first strand cDNA, reverse transcriptases (RTs) combine an RNA template with a brief primer complementary to the 3' end of the RNA.
Reverse transcriptase, an HIV enzyme, is blocked by nucleoside reverse transcriptase inhibitors (NRTIs). HIV reverse transcriptase is bound to and blocked by non-nucleoside reverse transcriptase inhibitors (NNRTIs). Reverse transcription is the process by which HIV turns RNA into DNA. HIV cannot replicate when reverse transcriptase and reverse transcription are blocked.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V54257 | (+)-Dihydrocalanolide A (DHCal A; NSC 678323) | 183904-53-2 | (+)-Dihydrocalanolide A (DHCal A; NSC 678323) is an orally bioavailable, non-nucleoside reverse transcriptase inhibitor. |
|
V2865 | BMS-538203 | 543730-41-2 | BMS-538203 is a novel and highly efficient HIV integrase inhibitor that is being developed as an antiviral agent. |
|
V1833 | BMS-707035 | 729607-74-3 | BMS-707035 is a novel, potent, specific, and reversible inhibitor of HIV-I integrase (IN) with IC50 of 15 nM. |
|
V88314 | EFdA-TP tetralithium | EFdA-TP tetralithium is a potent nucleoside reverse transcriptase (RT) inhibitor. | |
|
V88317 | HIV-1 inhibitor-65 | HIV-1 inhibitor-65 (compound 3c) is an inhibitor of HIV-1 (EC50: 2.9 nM) and an activator of protein kinase C (PKC). | |
|
V88316 | HIV-1 inhibitor-66 | HIV-1 inhibitor-66 is an orally active non-nucleoside reverse transcriptase inhibitor (NNRTI). | |
|
V54261 | Inophyllum B ((+)-Inophyllum B) | 41135-06-2 | Inophyllum B ((+)-Inophyllum B) is a potent HIV reverse transcriptase inhibitor (antagonist) with IC50 of 38 nM. |
|
V88256 | Lamivudine triphosphate | 143188-53-8 | Lamivudine triphosphate (3TCTP) is a phosphorylated Lamivudine (nucleoside analog). |
|
V54268 | M-MLV Reverse transcriptase (M-MLV RT) | 9068-38-6 | M-MLV Reverse transcriptase (M-MLV RT) is a reverse transcriptase originally developed from Moloneymurineleukemiavirus (MoMLV). |
|
V1834 | MK-2048 | 869901-69-9 | MK-2048 is a potent andsecond-generation inhibitor of integrase (IN) and INR263K with IC50 of 2.6 nM and 1.5 nM, respectively. |
|
V88315 | MK-8527 | 1810869-23-8 | MK-8527 is an HIV inhibitor and a nucleoside reverse transcriptase translocation inhibitor (NRTTI). |
|
V88318 | NNRT-IN-4 | NNRT-IN-4 (Compound 10p) is a non-nucleoside reverse transcriptase (NNRT) inhibitor with an IC50 of 0.713 µM for HIV-1 RT. | |
|
V94613 | NNRT-IN-5 | 3032803-00-9 | NNRT-IN-5 (compound 10d) is an oral non-nucleoside reverse transcriptase inhibitor. |
|
V34734 | Tenofovir diphosphate (TFV-DP) | 166403-66-3 | Tenofovir diphosphate (TFV-DP) is an ATP-competitive inhibitor of DNA polymerases and a substrate of HIV type 1 (HIV-1) reverse transcriptase (RT). |
|
V34735 | Tenofovir diphosphate triethylamine (TFV-DP triethylamine) | 2122333-63-3 | Tenofovir diphosphate triethylamine (TFV-DP triethylamine) is an ATP-competitive inhibitor of DNA polymerases and a substrate of HIV type 1 (HIV-1) reverse transcriptase (RT). |
|
V5189 | Lersivirine (UK-453061) | 473921-12-9 | Lersivirine (formerly UK-453061; UK453061) is a novel next-generation and potent non-nucleoside reverse transcriptase inhibitor (NNRTI) with IC50 of 119 nM and a unique resistance profile. |
|
V1828 | Etravirine (R165335; TMC125) | 269055-15-4 | Etravirine (formerly TMC-125; R-165335) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV. |
|
V2143 | Rilpivirine HCl (TMC278; DB08864) | 700361-47-3 | Rilpivirine HCl (TMC-278;R-278474 HCl; DB-08864; Edurant; Rekambys; Cabenuva), the hydrochloride salt of Rilpivirine, is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that has been approved for thetreatment ofHIV-1 infections. |
|
V1819 | Rilpivirine (R278474; TMC278) | 500287-72-9 | Rilpivirine (formerly known as R278474; TMC278; DB08864; Edurant; Rekambys; Cabenuva), an approved HIV drug, is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that has been widely usedfor thetreatment ofHIV-1 infection. |
|
V1835 | Cabotegravir (GSK744; GSK1265744) | 1051375-10-0 | Cabotegravir (formerly GSK744; GSK1265744; GSK-744; GSK-1265744;Rekambys; Cabenuva) is a potent, orally bioavailable and long-acting inhibitor of HIV integrase approved in 2020 for the treatment and prevention of HIV infection. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
